Dr. Bo Shen 沈波
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of digestive and respiratory system tumors, including tumor genotyping and targeted therapy.
Dr. Shen holds an MD and serves as Chief Physician and Researcher at Jiangsu Cancer Hospital. A doctoral supervisor, Dr. Shen has led over ten research projects and published more than 80 articles. Dr. Shen is an editor of several clinical books on oncology and has received multiple awards for new technology introduction from the Jiangsu Health Commission.
Professional roles
- Vice Chair, Tumor Recurrence and Metastasis Committee, Jiangsu Anti-Cancer Association
- Standing Committee Member, Clinical Chemotherapy Committee, China Anti-Cancer Association
- Member, Lung Cancer Committee, China Anti-Cancer Association
- Chair, Translational Medicine Branch, Jiangsu Immunology Society
Name order: in Chinese the family name comes first (Shen Bo). Papers usually list the name as Bo Shen or Shen B.
Selected publications
124 papers on PubMed matched by name and affiliation; 39 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Imaging Inform Med, 2026 (senior author): Teacher-Referenced Heatmap Coverage for Auditing Attribution Shifts in Updated CT Classifiers. PubMed 42773337
- J Immunother Cancer, 2026 (senior author): PGE2-mediated NK cell reprogramming drives acquired immunotherapy resistance in lung adenocarcinoma. PubMed 42586608
- Nat Commun, 2026 (first author): Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM). PubMed 41554745
- Anticancer Agents Med Chem, 2026 (senior author): FN-1501 Synergistically Enhances Almonertinib Efficacy in EGFR-TKI-Resistant Lung Adenocarcinoma through Ferroptosis Induction. PubMed 41293947
- Anticancer Agents Med Chem, 2026 (senior author): The EP300-Targeting Drug CCS1477 Inhibits the Growth and Development of Diffuse Large B-Cell Lymphoma by Promoting Apoptosis and Mitophagy to Reduce Drug Resistance. PubMed 41088985
- Cell Death Dis, 2025 (senior author): Suppressing the OTUD7A/KDM5B/GABPA axis enhances the sensitivity of cisplatin through inducing ferroptosis in KRAS-mutant LUAD. PubMed 41422226
- Front Immunol, 2025 (senior author): SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer. PubMed 41488634
- J Immunother Cancer, 2025 (senior author): ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell lung cancer. PubMed 41073134
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion